Modulation of chemoimmunotherapy efficacy in non-small cell lung cancer by sex and histology: a real-world, patient-level analysis

Table 4 Survival analysis in NSCLC patients treated with chemoimmunotherapy

Immunotherapy Patients
	Multivariable Analysis^a (n = 1998)	Propensity Matched Analysis (n = 1072; 536 pairs)^a
	HR _adj (95% CI)	HR (95% CI)
Sex: Female/Male	0.79 (0.71–0.88)	0.84 (0.72–0.97)

^aadjusted for/propensity matched on sex, age at diagnosis, histology (adenocarcinoma, squamous, large cell or other), race (White, Black or Asian/other), Charlson-Deyo comorbidity index, receipt of palliative radiation, year of diagnosis, insurance status (uninsured, privately insured, publically insured, unknown), and median household income for patient’s area of residence (< $38,000, $38,000–$47,999, $48,000–$62,999, >$63,000)
Abbreviations: HR Hazard Ratio, CI Confidence Interval

ISSN: 1471-2407